NDAORALCAPSULEPriority Review
Approved
Mar 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
NALFON (fenoprofen calcium) by Teva is analgesic, anti-inflammatory, and antipyretic properties. Approved for rheumatoid arthritis. First approved in 1976.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NALFON (fenoprofen calcium) is an oral NSAID approved in 1976 for rheumatoid arthritis that works by inhibiting cyclooxygenase (COX-1 and COX-2) to reduce prostaglandin synthesis. It provides analgesic, anti-inflammatory, and antipyretic effects by decreasing prostaglandin-mediated pain and inflammation in peripheral tissues.
$0.023BPart D
LOE ApproachingWith LOE approaching and only $23K in Part D spending, NALFON faces minimal commercial opportunity; expect a small, defensive brand team focused on maintaining existing patient populations rather than growth.
Mechanism of Action
analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of FENOPROFEN CALCIUM, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Fenoprofen is a potent inhibitor of prostaglandin synthesis in vitro.…
Indications (1)
Career Relevance
Worked on NALFON at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.